Insulin therapy for adult patients with type 2 diabetes mellitus: a position statement of the Korean Diabetes Association, 2017

被引：4
作者：
Lee, Byung-Wan [1 ]
Kim, Jin Hwa [2 ]
Ko, Seung-Hyun [3 ]
Hur, Kyu Yeon [4 ]
Kim, Nan-Hee [5 ]
Rhee, Sang Youl [6 ]
Kim, Hyun Jin [7 ]
Moon, Min Kyong [8 ]
Park, Seok-O [9 ]
Choi, Kyung Mook [5 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[2] Chosun Univ, Dept Internal Med, Coll Med, Div Endocrinol & Metab, Gwangju, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Endocrinol & Metab,Dept Internal Med, Seoul, South Korea
[5] Korea Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[6] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, Seoul, South Korea
[7] Chungnam Natl Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Daejeon, South Korea
[8] Seoul Natl Univ, Seoul Metropolitan Govt, Boramae Med Ctr, Div Endocrinol & Metab,Dept Internal Med, Seoul, South Korea
[9] Gwangmyeong Sungae Hosp, Dept Internal Med, Gwangmyeong, South Korea
来源：
KOREAN JOURNAL OF INTERNAL MEDICINE | 2017年 / 32卷 / 06期
关键词：
Clinical practice guideline; Diabetes mellitus; type; 2; Hypoglycemic agents; Insulin; Korea; PEPTIDE-1 RECEPTOR AGONIST; ORAL ANTIDIABETIC DRUGS; GLYCEMIC CONTROL; BASAL INSULIN; PREMIXED INSULIN; BOLUS INSULIN; SULFONYLUREA; METFORMIN; REGIMENS; MANAGEMENT;
D O I：
10.3904/kjim.2017.314
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM.
引用
收藏
页码：967 / 973
页数：7
相关论文
共 39 条
  • [1] Insulin glargine compared with premixed insulin for management of insulin-naive type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study
    Aschner, Pablo
    Sethi, Bipin
    Gomez-Peralta, Fernando
    Landgraf, Wolfgang
    Loizeau, Virginie
    Dain, Marie-Paule
    Pilorget, Valerie
    Comlekci, Abdurrahman
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (06) : 838 - 845
  • [2] Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)
    Charbonnel, Bernard
    DeFronzo, Ralph
    Davidson, Jaime
    Schmitz, Ole
    Birkeland, Kare
    Pirags, Valdis
    Scheen, Andre
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (05) : 2163 - 2171
  • [3] Comparison of Antidiabetic Regimens in Patients with Type 2 Diabetes Uncontrolled by Combination Therapy of Sulfonylurea and Metformin: Results of the MOHAS Disease Registry in Korea
    Choi, Sung Hee
    Oh, Tae Jung
    Jang, Hak Chul
    [J]. DIABETES & METABOLISM JOURNAL, 2017, 41 (03) : 170 - 178
  • [4] Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis
    Clar, Christine
    Royle, Pamela
    Waugh, Norman
    [J]. PLOS ONE, 2009, 4 (07):
  • [5] Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
    Devineni, D.
    Morrow, L.
    Hompesch, M.
    Skee, D.
    Vandebosch, A.
    Murphy, J.
    Ways, K.
    Schwartz, S.
    [J]. DIABETES OBESITY & METABOLISM, 2012, 14 (06) : 539 - 545
  • [6] Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
    Diamant, Michaela
    Nauck, Michael A.
    Shaginian, Rimma
    Malone, James K.
    Cleall, Simon
    Reaney, Matthew
    de Vries, Danielle
    Hoogwerf, Byron J.
    MacConell, Leigh
    Wolffenbuttel, Bruce H. R.
    [J]. DIABETES CARE, 2014, 37 (10) : 2763 - 2773
  • [7] Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study
    Dieuzeide, Guillermo
    Chuang, Lee-Ming
    Almaghamsi, Abdulrahman
    Zilov, Alexey
    Chen, Jian-Wen
    Lavalle-Gonzalez, Fernando J.
    [J]. PRIMARY CARE DIABETES, 2014, 8 (02) : 111 - 117
  • [8] Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial
    Douek, IF
    Allen, SE
    Ewings, P
    Gale, EAM
    Bingley, PJ
    [J]. DIABETIC MEDICINE, 2005, 22 (05) : 634 - 640
  • [9] Glucagon-like peptide-1 receptor agonist and basal insulin combination tre atment for the management of type 2 diabetes: a systematic review and meta-analysis
    Eng, Conrad
    Kramer, Caroline K.
    Zinman, Bernard
    Retnakaran, Ravi
    [J]. LANCET, 2014, 384 (9961) : 2228 - 2234
  • [10] An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
    Fonseca, V.
    Gill, J.
    Zhou, R.
    Leahy, J.
    [J]. DIABETES OBESITY & METABOLISM, 2011, 13 (09) : 814 - 822
1234